TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8277768
Drug: Cimetidine with
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine with DMSO (500 mg at bedtime)
Study: 8277768
Drug: Cimetidine with
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine with allopurinol (50 mg at bedtime)
Study: 2973595
Drug: Cefotaxime-Amikacin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime-Amikacin combination
Study: 30016417
Drug: Active-suspension seat
Normalized name: activated charcoal Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active-suspension seat
Study: 30016393
Drug: Industry-standard air-suspension
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Industry-standard air-suspension seat
Study: 28851779
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVA) with sham photodynamic therapy (sPDT)
Study: 18458204
Drug: Induction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of catecholamine depletion (CD) by oral administration of alpha‐methylparatyrosine
Study: 18458204
Drug: Sham depletion
Normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham depletion using identical capsules containing hydrous lactose
Study: 15071276
Drug: Optimized medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized medical therapy (ACE inhibitors, beta-blockers, aldosterone antagonists)
Study: 15071269
Drug: Prophylactic ICD
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic ICD therapy
Study: 8799518
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 50 micrograms kg‐1 of diamorphine
Study: 8799518
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 200 micrograms kg‐1 of diamorphine
Study: 8799518
Drug: M3G: morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M3G: morphine steady-state plasma concentration ratio
Study: 8799518
Drug: M6G: morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M6G: morphine steady-state plasma concentration ratio
Study: 2846132
Drug: Propranolol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (both doses)
Study: 30770034
Drug: Calmer treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calmer treatment, n = 5
Study: 26615376
Drug: 15 mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/Kg intravenous valproate
Study: 22495786
Drug: Oral alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alcohol (1 g/kg) administration before ART
Study: 22495786
Drug: Post-ART alcohol
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-ART alcohol administration
Study: 18091486
Drug: McKenzie treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: McKenzie treatment
Study: 26188020
Drug: Oral antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antioxidant cocktail (AOC)
Study: 23107171
Drug: Multiphasic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiphasic injection protocol (protocol II) with 89 mL Ioversol
Study: 23107171
Drug: Standard uniphasic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard uniphasic injection protocol (protocol I) with 100 mL Ioversol
Study: 23107171
Drug: Multiphasic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiphasic injection protocol (protocol II)
Study: 23107171
Drug: Standard uniphasic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard uniphasic injection protocol (protocol I)
Study: 23107171
Drug: Multiphasic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiphasic injection technique
Study: 21969502
Drug: Gemcitabine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine alone (1,000 mg/m(2)/wk for weeks 1 to 6, followed by 1 week rest, then for 3 of 4 weeks)
Study: 21969502
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus radiotherapy (600 mg/m(2)/wk for weeks 1 to 5, then 4 weeks later 1,000 mg/m(2) for 3 of 4 weeks plus radiotherapy starting on day 1, 1.8 Gy/Fx for total of 50.4 Gy)
Study: 18335584
Drug: Inflamed tooth
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inflamed tooth and implant sites
Study: 7821319
Drug: Oral amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiodarone (single loading dose of 25.7 +/- 0.9 mg.kg-1 body weight)
Study: 7821319
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (bolus infusion of 3-5 mg.kg-1 over 30 min, followed by continuous infusion of 10-15 mg.kg-1 for 24 h)
Study: 3209830
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic therapy (penicillin-gentamicin-metronidazole)
Study: 30225762
Drug: Religious psychotherapy
Normalized name: red delicious apple allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Religious psychotherapy emphasizing the importance of prayers (reading prayers 15 and 23 of the SahifehSajjadiyeh book at the beginning of treatment sessions)
Study: 26421385
Drug: MTX and
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX and ω‐3 fatty acids (1000 mg/d)
Study: 22805060
Drug: Dopamine (amphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (amphetamine administration)
Study: 20818716
Drug: Plasma filtration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma filtration (twice weekly in Weeks 1, 2, 4, 7, and 10)
Study: 11437398
Drug: Chlorambucil (CB):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (CB): 10 mg daily for 6 weeks, followed by a 2‐week interval, with 3 subsequent 2‐week treatment periods at the same dose, separated by 2‐week intervals
Study: 11437398
Drug: Chlorambucil (CB)
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil (CB) given concurrently with interferon (IFN) at a dose of 3 x 10(6) units thrice weekly, subcutaneously, throughout the 18‐week treatment period
Study: 11437398
Drug: Maintenance IFN
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance IFN at the same dose and schedule as initial treatment
Study: 9488619
Drug: Clodronate 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1600 mg daily
Study: 27569526
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning tool predicting treatment outcomes based on patient-reportable information
Study: 12805393
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 64 mg daily
Study: 12805393
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 96 mg daily
Study: 12805393
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 192 mg daily
Study: 12805393
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 384 mg daily
Study: 10485241
Drug: Flow rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flow rate of 2.0 ml/s
Study: 10485241
Drug: Flow rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flow rate of 3.0 ml/s
Study: 10485241
Drug: Flow rates
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow rates of 2.0 ml/s, 3.0 ml/s, and 4.0 ml/s
Study: 10485241
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 120 ml contrast medium with a flow rate of 3.0 ml/s
Study: 8561334
Drug: Etidocaine 1%
Normalized name: etidocaine 1% preservative-free injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidocaine 1% (10 mL)
Study: 28592147
Drug: Mixed strategy
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed strategy combining the same outpatient program associated with a weekly multidisciplinary intervention
Study: 22804972
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate (50 mg/kg of fat-free mass per day)
Study: 15067698
Drug: Unmanipulated drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmanipulated drug
Study: 11144994
Drug: Scopolamine 0.5
Normalized name: scopolamine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.5 mg as an intravenous (i.v.) infusion over 15 minutes
Study: 11144994
Drug: Scopolamine 0.5
Normalized name: scopolamine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.5 mg as an intramuscular (i.m.) injection
Study: 6448620
Drug: Atropine (large
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (large doses)
Study: 6448620
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (conventional doses)
Study: 29458401
Drug: Ding-Kun-Dan (DKD)
Normalized name: Ding xiang
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ding-Kun-Dan (DKD) pre-treatment for 3 months before IVF/ICSI
Study: 17550787
Drug: quetiapine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine monotherapy (n=19)
Study: 17550787
Drug: quetiapine add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine add-on therapy (n=22)
Study: 15931573
Drug: Pterocarpus marsupium
Normalized name: Pterocarpus marsupium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pterocarpus marsupium extract (PM extract) 450 mg
Study: 12929273
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg via a 15-minute infusion)
Study: 12929273
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg via a two-hour infusion)
Study: 8842930
Drug: Geriatrics-focused acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geriatrics-focused acute medicine inpatient rotation with a geriatrics-trained internist attending (n = 44)
Study: 8842930
Drug: Geriatrics-focused acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geriatrics-focused acute medicine inpatient rotation with a non-geriatrics-trained internist attending (n = 25)
Study: 1530836
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 40 micrograms ipratropium and 100 micrograms fenoterol
Study: 6238551
Drug: Metoclopramide, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide, 10 mg
Study: 6238551
Drug: Cimetidine, 300
Normalized name: Cimetidine, 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 300 mg
Study: 6238551
Drug: Metoclopramide, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide, 10 mg and Cimetidine, 300 mg
Study: 3946851
Drug: Slow-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release theophylline (10 +/- 1 mg/kg, orally)
Study: 26829597
Drug: Lamotrigine augmentation
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine augmentation therapy at 100 mg/d for subjects not taking valproate and 75 mg/d for subjects taking valproate.
Study: 26829597
Drug: Lamotrigine augmentation
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine augmentation therapy (specific doses based on valproate use).
Study: 18564199
Drug: Serotonin-noradrenalin reuptake
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin-noradrenalin reuptake inhibitor (SNRI)
Study: 1604872
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) administered as a single daily dose
Study: 1604872
Drug: Divided doses
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided doses of valproic acid (VPA) thrice daily
Study: 2857803
Drug: Dipyridamole 75
Normalized name: dipyridamole 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 75 mg and Aspirin 330 mg
Study: 30482552
Drug: Clonidine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 3 μg.kg−1 with bupivacaine 0.165%
Study: 30482552
Drug: Clonidine 1
Normalized name: apraclonidine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 1 μg.kg−1 with bupivacaine 0.165%
Study: 30482552
Drug: Clonidine 2
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 2 μg.kg−1 with bupivacaine 0.165%
Study: 30342902
Drug: Placebo bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bleaching (ACP gel) followed by resin infiltration
Study: 27050244
Drug: 70 ml
Normalized name: ALCOHOL 70 mL TOPICAL SWAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 ml of 'BEET It Sport' nitrate shot containing 6.4 millimoles (mmol.L) or 400 mg of nitrate
Study: 24840756
Drug: Caffeine therapy
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine therapy
Study: 17521311
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg daily for 2 weeks
Study: 16390760
Drug: HT +
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HT + FA (0.625 mg conjugated equine estrogen with 2.5 mg medroxyprogesterone acetate daily and 5 mg folic acid/day)
Study: 16390760
Drug: HT +
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HT + placebo (0.625 mg conjugated equine estrogen with 2.5 mg medroxyprogesterone acetate daily)
Study: 12015519
Drug: Parenteral 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral 17beta‐estradiol (7.5 microg/24 h) delivered by a vaginal ring (Estring) for 12 months
Study: 12015519
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for 12 months
Study: 10725861
Drug: Immunostains for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunostains for prostate-specific antigen, MUC-2, androgen receptor, and Ki-67
Study: 1623678
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg/day for one month)
Study: 6202678
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg subcutaneous disulfiram implant
Study: 6202678
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg subcutaneous disulfiram implant
Study: 6202678
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg subcutaneous disulfiram implant
Study: 26990867
Drug: Topical oestriol
Normalized name: Oestriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oestriol cream for 6 weeks
Study: 10901475
Drug: Pilocarpine 2%
Normalized name: PILOCARPINE 2% SOLN,OPH
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine 2% three times daily
Study: 9488944
Drug: THP (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: THP (20 mg dissolved in 40 ml saline or 5% dextrose, administered intravesically once a week for 10 weeks)
Study: 9488944
Drug: Control (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (40 ml saline administered intravesically once a week for 10 weeks)
Study: 8405521
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen/10 mg progestin
Study: 8290177
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg conjugated equine estrogen
Study: 30349198
Drug: GLA5PR GLARS-NF1
Normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GLA5PR GLARS-NF1 150 mg
Study: 30349198
Drug: GLA5PR GLARS-NF1
Normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GLA5PR GLARS-NF1 300 mg
Study: 30349198
Drug: GLA5PR GLARS-NF1
Normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GLA5PR GLARS-NF1 450 mg
Study: 30349198
Drug: GLA5PR GLARS-NF1
Normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GLA5PR GLARS-NF1 600 mg
Study: 30349198
Drug: GLA5PR GLARS-NF1
Normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GLA5PR GLARS-NF1 150-450 mg
Study: 30349198
Drug: GLA5PR GLARS-NF1
Normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GLA5PR GLARS-NF1 150-600 mg
Study: 24008819
Drug: 2-1 intramuscular
Normalized name: Hutbti3_2_1
DrugBank: Romilkimab (DB16318)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-1 intramuscular (IM) regimen (group A)
Study: 23872591
Drug: Statins plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins plus niacin (1500 mg daily)
Study: 21178911
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg hyperbaric bupivacaine plus 25 µg fentanyl
Study: 21178911
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg hyperbaric levobupivacaine plus 25 µg fentanyl
Study: 17143000
Drug: Systemic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroid treatment (SST)
Study: 17143000
Drug: Nonsteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroid treatment (NST)
Study: 10969306
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 50 mg hyperbaric lidocaine, 5% (n = 10)
Study: 10969306
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 50 mg hyperbaric lidocaine, 5%
Study: 7871905
Drug: Blocking 5-HT3
Normalized name: bentoquatam
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blocking 5-HT3 receptors with ondansetron or tropisetron-hydrochloride
Study: 3340422
Drug: 1.1 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1 micrograms/kg fentanyl (open and double-blind intravenous infusion)
Study: 29603299
Drug: One-visit root
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-visit root canal treatment with 2% chlorhexidine (CHX) final rinse
Study: 29603299
Drug: Two-visit root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-visit root canal treatment with calcium hydroxide (CH) dressing
Study: 28302101
Drug: Culturally-grounded lifestyle
Normalized name: Turmeric,ground
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally-grounded lifestyle intervention (weekly nutrition and wellness sessions, physical activity sessions twice a week for 6 months, followed by 3 months of booster sessions)
Study: 21415398
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A injection(s) plus a 4‐week therapy program
Study: 21415398
Drug: Therapy program
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy program alone
Study: 18075401
Drug: 1-g EMLA
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-g EMLA cream applied 1 hour before the procedure
Study: 18075401
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied 1 hour before the procedure
Study: 18075401
Drug: 1-g EMLA
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-g EMLA cream
Study: 14746532
Drug: Rituximab in
Normalized name: rituximab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab in combination with standard chemotherapy
Study: 11683282
Drug: Subcutaneous curettage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous curettage
Study: 11683282
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of botulinum toxin A (BT-A)
Study: 26124084
Drug: TPF induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF induction chemotherapy (75mg/m2 docetaxel d1, 75mg/m2 cisplatin d1, and 750mg/m2/day 5‐fluorouracil d1‐5) followed by radical surgery and post‐operative radiotherapy
Study: 22025880
Drug: Probiotic goat
Normalized name: Goat milk
DrugBank: Goat milk (DB10542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic goat yogurt with 10(9) CFU/mL Bifidobacterium longum
Study: 18481713
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (oral administration according to WHO Three Step Administration Principle: aspirin for mild pain, codeine for moderate pain, morphine for severe pain)
Study: 14579873
Drug: Control manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control manual toothbrush (Oral-B Cross Action)
Study: 1953532
Drug: Oral vaccine
Normalized name: RotaTeq Oral Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vaccine containing killed Haemophilus influenzae
Study: 7447203
Drug: Low-dose verapamil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose verapamil (0.075 mg/kg body weight)
Study: 7447203
Drug: High-dose verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose verapamil (0.15 mg/kg body weight)
Study: 30448451
Drug: Insulin degludec/insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin degludec/insulin aspart (IDegAsp) once-daily (OD)